Pharmaceutical companies risk enforcement action under the Trump Administration’s final rule on list price disclosures in direct-to-consumer TV ads if they think it is enough to observe the Pharmaceutical Research and Manufacturers of America’s voluntary disclosure program, according to HHS Secretary Alex Azar.
The final rule requiring DTC TV ads to disclose list prices was released by the Centers for Medicare and Medicaid Services 8 May with few changes compared to the proposed rule